Mizuho Financial Group Inc. Sponosred ADR (Japan) vs Merck & Co., Inc. — how do they compare? Mizuho Financial Group Inc. Sponosred ADR (Japan) trades at $10.41 (market cap $127.85B), while Merck & Co., Inc. trades at $141.98 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 2.7× Mizuho Financial Group Inc. Sponosred ADR (Japan)'s market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Mizuho Financial Group Inc. Sponosred ADR (Japan) for 0 Days and Merck & Co., Inc. for 98 Days on average.
| MFG | MRK | |
|---|---|---|
Market Cap | $127.85B | $351.28B |
Volume | 3,950,750 | 7,969,665 |
Sector | Financials | Health |
52-Week High | $11.45 | $156.43 |
52-Week Low | $6.09 | $82.49 |
Typical Hold Time | 0 Days | 98 Days |
Enterprise Value | $35.14T | $398.04B |
Dividend Yield | 1.72% | 2.39% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Mizuho Financial Group is a Japanese financial services company offering banking, trust, securities, and asset management services. It serves retail, corporate, and institutional clients globally.
Read more on MFG →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →